ReviewFrontiers in cell and developmental biology2026
Cellular senescence of renal tubular epithelial cells in diabetic kidney disease: emerging mechanisms and targeted interventions.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease (ESKD), and while current standard treatment strategies can slow disease progression, they are still unable to reverse progressive structural damage to the kidneys. Emerging evidence indicates that the senescence of renal tubular epithelial cells (RTECs) is not only a central feature of early-stage DKD but also a key pathological mechanism driving renal interstitial fibrosis and progressive kidney function decline. This review systematically elucidates the emerging molecular networks governing RTEC senescence within the DKD microenvironment. Specifically, it thoroughly explores the roles of glucolipotoxicity induced by metabolic dysregulation, persistent reactive oxygen species (ROS) stress, DNA damage, senescence-associated secretory phenotype (SASP)-mediated paracrine toxicity, abnormal epigenetic modifications, and failure of endogenous protective mechanisms such as mitophagy. Furthermore, this review provides a brief overview of current potential therapeutic strategies for delaying or eliminating senescent cells, covering research progress and clinical limitations related to sodium-glucose cotransporter 2 (SGLT2) inhibitors, metformin, mesenchymal stem cell (MSC) therapy, and potential natural products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.